{'52WeekChange': 16.811594,
 'SandP52WeekChange': 0.0644362,
 'address1': '395 Oyster Point Boulevard',
 'address2': 'Suite 405',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 12.39,
 'askSize': 4000,
 'averageDailyVolume10Day': 28951312,
 'averageVolume': 23682411,
 'averageVolume10days': 28951312,
 'beta': 0.409578,
 'beta3Year': None,
 'bid': 12.36,
 'bidSize': 800,
 'bookValue': 0.435,
 'category': None,
 'circulatingSupply': None,
 'city': 'South San Francisco',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 13.12,
 'dayLow': 12,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -110.901,
 'enterpriseToRevenue': 120.157,
 'enterpriseValue': 883992320,
 'exDividendDate': 1352419200,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fax': '650-871-8580',
 'fiftyDayAverage': 7.6254287,
 'fiftyTwoWeekHigh': 17.49,
 'fiftyTwoWeekLow': 0.25,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 73639067,
 'forwardEps': 0.1,
 'forwardPE': 122.9,
 'fromCurrency': None,
 'fullTimeEmployees': 14,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'heldPercentInsiders': 0.01209,
 'heldPercentInstitutions': 0.36233002,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': 1518566400,
 'lastSplitFactor': '1:11',
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/vaxart.com',
 'longBusinessSummary': 'Vaxart, Inc., a clinical-stage company, engages in '
                        'the discovery and development of oral recombinant '
                        'protein vaccines based on its proprietary oral '
                        "vaccine platform. The company's product pipeline "
                        'includes tablet vaccines that are designed to protect '
                        'against norovirus, seasonal influenza, and '
                        'respiratory syncytial virus. It is also developing '
                        'therapeutic immune-oncology vaccines for cervical '
                        'cancer and dysplasia caused by human papillomavirus. '
                        'Vaxart, Inc. has a research collaboration agreement '
                        'with Janssen Vaccines & Prevention B.V. (Janssen) to '
                        "evaluate the company's proprietary oral vaccine "
                        'platform for the Janssen universal influenza vaccine '
                        'program. The company is headquartered in South San '
                        'Francisco, California.',
 'longName': 'Vaxart, Inc.',
 'market': 'us_market',
 'marketCap': 1340765312,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_37819645',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -18603000,
 'nextFiscalYearEnd': 1640908800,
 'open': 13.01,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '650-550-3500',
 'previousClose': 13.85,
 'priceHint': 2,
 'priceToBook': 28.252872,
 'priceToSalesTrailing12Months': 182.24348,
 'profitMargins': -2.52861,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 13.12,
 'regularMarketDayLow': 12,
 'regularMarketOpen': 13.01,
 'regularMarketPreviousClose': 13.85,
 'regularMarketPrice': 13.01,
 'regularMarketVolume': 14406734,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 109094000,
 'sharesPercentSharesOut': 0.0713,
 'sharesShort': 6767576,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 3293201,
 'shortName': 'Vaxart, Inc. - Common Stock',
 'shortPercentOfFloat': 0.09810001,
 'shortRatio': 0.24,
 'startDate': None,
 'state': 'CA',
 'strikePrice': None,
 'symbol': 'VXRT',
 'threeYearAverageReturn': None,
 'toCurrency': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -0.533,
 'twoHundredDayAverage': 3.3081295,
 'volume': 14406734,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://vaxart.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '94080'}